These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 31036317

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G.
    Oncotarget; 2016 Apr 19; 7(16):21982-90. PubMed ID: 26980736
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccarani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, Soverini S.
    J Cancer Res Clin Oncol; 2015 May 19; 141(5):887-99. PubMed ID: 25367136
    [Abstract] [Full Text] [Related]

  • 5. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R, Galal A.
    BMC Cancer; 2018 Nov 12; 18(1):1097. PubMed ID: 30419862
    [Abstract] [Full Text] [Related]

  • 6. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
    Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, Haferlach C, Haferlach T.
    Haematologica; 2016 Jul 12; 101(7):830-8. PubMed ID: 27102501
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM, Chomel JC, Coiteux V, Dulucq S, Escoffre-Barbe M, Etancelin P, Etienne G, Hayette S, Millot F, Nibourel O, Nicolini FE, Réa D, pour la France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) et le Groupe des biologistes moléculaires des hémopathies malignes (GBMHM).
    Bull Cancer; 2020 Jan 12; 107(1):113-128. PubMed ID: 31353136
    [Abstract] [Full Text] [Related]

  • 9. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
    Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, Vergílio B, Silveira RA, Oliveira-Duarte V, Lorand-Metze I, De Souza CA, Pagnano KB.
    Clinics (Sao Paulo); 2015 Aug 12; 70(8):550-5. PubMed ID: 26247667
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G, Dulucq S, Huguet F, Schmitt A, Lascaux A, Hayette S, Fort MP, Sujobert P, Bijou F, Morisset S, Tavitian S, Bidet A, Turcq B, Robbesyn F, Chollet C, Belloc F, Durrieu F, Mahon FX, Nicolini FE.
    Cancer Med; 2019 Sep 12; 8(11):5173-5182. PubMed ID: 31350815
    [Abstract] [Full Text] [Related]

  • 13. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Mascarenhas CC, Cunha AF, Miranda EC, Zulli R, Silveira RA, Costa FF, Pagnano KB, De Souza CA.
    Leuk Lymphoma; 2009 Jul 12; 50(7):1148-54. PubMed ID: 19557636
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR, Yang F, Press RD.
    Methods Mol Biol; 2013 Jul 12; 999():25-39. PubMed ID: 23666688
    [Abstract] [Full Text] [Related]

  • 18. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.
    Kastner R, Zopf A, Preuner S, Pröll J, Niklas N, Foskett P, Valent P, Lion T, Gabriel C.
    Eur J Cancer; 2014 Mar 12; 50(4):793-800. PubMed ID: 24365090
    [Abstract] [Full Text] [Related]

  • 19. Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.
    Dey S, Basu S, Shah S, Bhattacharyya D, Gupta PP, Acharjee M, Roychoudhury S, Nath S.
    Cancer Treat Res Commun; 2022 Mar 12; 33():100635. PubMed ID: 36155130
    [Abstract] [Full Text] [Related]

  • 20. Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
    Romzova M, Smitalova D, Tom N, Jurcek T, Culen M, Zackova D, Mayer J, Racil Z.
    Br J Haematol; 2020 May 12; 189(3):469-474. PubMed ID: 32037516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.